Clobetasol propionate
- Generic Name
- Clobetasol propionate
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32ClFO5
- CAS Number
- 25122-46-7
- Unique Ingredient Identifier
- 779619577M
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.
Clobetasol Propionate was granted FDA approval on 27 December 1985.
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Associated Conditions
- Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis
- Associated Therapies
- -
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 40
- Registration Number
- NCT06742333
- Locations
- 🇫🇷
CHU de Nice - Hôpital de l'Archet, Nice, Alpes-Maritimes, France
🇫🇷Hôpital Edouard Herriot, Lyon, France
🇫🇷Hôpital Saint-Joseph, Marseille, France
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Salvat
- Target Recruit Count
- 60
- Registration Number
- NCT05724446
- Locations
- 🇪🇸
Hospìtal Sant Joan de Deu, Barcelone, Spain
Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
- Target Recruit Count
- 190
- Registration Number
- NCT05706870
- Locations
- 🇹🇷
Uludag University Faculty of Medicine, Bursa, Turkey
🇹🇷Ataturk University Research Hospital, Erzurum, Turkey
🇹🇷Pamukkale University Faculty of Medicine, Denizli, Turkey
Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Fundación Eduardo Anitua
- Target Recruit Count
- 30
- Registration Number
- NCT05364515
Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 39
- Registration Number
- NCT04649697
- Locations
- 🇪🇬
Cairo University, Cairo, Egypt
Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Malmö University
- Target Recruit Count
- 90
- Registration Number
- NCT04364555
- Locations
- 🇸🇪
Oral surgery, Universityhospital of Scania, Lund, Sweden
🇸🇪Oral Surgery and oral medicine, Malmö University, Malmö, Sweden
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Salvat
- Target Recruit Count
- 215
- Registration Number
- NCT04249076
- Locations
- 🇺🇸
Inland Eye Specialists, Hemet, California, United States
🇺🇸Shah Eye Center, Mission, Texas, United States
🇺🇸Walman Eye Center, Sun City, Arizona, United States
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Salvat
- Target Recruit Count
- 250
- Registration Number
- NCT04246801
- Locations
- 🇺🇸
Arus Research at Cape Coral Eye Center, Cape Coral, Florida, United States
🇺🇸Black Hills Regional Eye Institute, Rapid City, South Dakota, United States
🇺🇸Wellish Vision Institute, Las Vegas, Nevada, United States
Intra-oral Treatment of OLP With Rivelin®-CLO Patches
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Dermtreat
- Target Recruit Count
- 140
- Registration Number
- NCT03592342
- Locations
- 🇮🇪
Cork University Dental School and Hospital, Cork, Ireland
🇺🇸QWay Research, Hialeah, Florida, United States
🇺🇸University of Pennsylvania Health System, Dept. Oral amd Maxillofacial Surgery, Philadelphia, Pennsylvania, United States
Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 40
- Registration Number
- NCT03535233
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.